{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(1)"],"submitter":["Brockbank J"],"funding":["H. Lundbeck A/S"],"pubmed_abstract":["<h4>Background</h4>Major depressive disorder (MDD) is associated with decreased patient well-being and symptoms that can cause substantial impairments in patient functioning and even lead to suicide. Worldwide, MDD currently causes the second-most years lived with disability and is predicted to become the leading cause of disability by 2030. Utility values, capturing patient quality of life, are required in economic evaluations for new treatments undergoing reimbursement submissions. We aimed to identify health state utility values (HSUVs) and disutilities in MDD for use in future economic evaluations of pharmacological treatments.<h4>Methods</h4>Embase, PubMed, Econlit, and Cochrane databases, plus gray literature, were searched from January 1998 to December 21, 2018, with no language or "],"journal":["Health and quality of life outcomes"],"pagination":["94"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7977292"],"repository":["biostudies-literature"],"pubmed_title":["Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review."],"pmcid":["PMC7977292"],"pubmed_authors":["Moss E","Vaughan J","Ahdesmaki O","Morup MF","Pedersen AM","Brockbank J","Brodtkorb TH","Krause T"],"additional_accession":[]},"is_claimable":false,"name":"Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.","description":"<h4>Background</h4>Major depressive disorder (MDD) is associated with decreased patient well-being and symptoms that can cause substantial impairments in patient functioning and even lead to suicide. Worldwide, MDD currently causes the second-most years lived with disability and is predicted to become the leading cause of disability by 2030. Utility values, capturing patient quality of life, are required in economic evaluations for new treatments undergoing reimbursement submissions. We aimed to identify health state utility values (HSUVs) and disutilities in MDD for use in future economic evaluations of pharmacological treatments.<h4>Methods</h4>Embase, PubMed, Econlit, and Cochrane databases, plus gray literature, were searched from January 1998 to December 21, 2018, with no language or ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T12:34:27.306Z","creation":"2025-04-04T12:34:27.306Z"},"accession":"S-EPMC7977292","cross_references":{"pubmed":["33736649"],"doi":["10.1186/s12955-021-01723-x"]}}